drugset / Trial / NCT01252745

Efficacy of an Intranasal Testosterone Product

NCT01252745

Phase 2 Completed 22 enrolled Acerus Pharmaceuticals Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial will compare the pharmacokinetic profile of testosterone after repeated intranasal administration of TBS-1 of different strengths in subjects with hypogonadism

Timeline

Start
2010-08
Primary completion
2010-11
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 10 mg Intranasal
Subject Testosterone Small molecule 11.25 mg Intranasal
Subject Testosterone Small molecule 13.5 mg Intranasal

Indications